

FDA accepted Nevro's Senza II for chronic pain treatment

09 January 2018 | News

High-frequency spinal cord stimulation therapy designed to provide pain relief, while eliminating unpleasant side effects of conventional systems



Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain.

The company announced that it has received FDA approval for its next-generation Senza II Spinal Cord Stimulation (SCS) System delivering HF10 therapy.

Nevro's Senza High-Frequency Spinal Cord Stimulation System delivers similar electrical pulses but at a higher rate than currently available devices.

Data from previous European clinical studies suggest that Nevro's proprietary high-frequency waveform may be effective in treating low back pain and other challenging types of chronic pain that often do not respond to conventional spinal cord stimulation.

Data also show that Nevro's technology can deliver pain relief without paresthesia and relive from unpleasant side effects.

The Senza II system offers the superior outcomes and clinical advantages of HF10 therapy through a smaller and more refined footprint while maintaining the performance and durability of the current Implantable Pulse Generator (IPG).

Superior, Non-Opioid Therapy Now Delivered in a Smaller and More Refined IPG.